益得複方吸入劑在台上市銷售 同步擴大海外布局website2646Apr 25, 20231 min readhttps://www.taiwan-healthcare.org/zh/news-detail?id=0rtnd87r8wslyezf&utm_source=line&utm_medium=b2b&utm_campaign=dailynews_0425
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offeringhttps://ir.bhtherapeutics.com/news-releases/news-release-details/blossomhill-therapeutics-announces-pricing-upsized-150-million
Alamar Biosciences Announces Pricing of Upsized Initial Public Offeringhttps://alamarbio.com/alamar-biosciences-announces-pricing-of-upsized-initial-public-offering/
BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancerhttps://www.businesswire.com/news/home/20250122706462/en/BlossomHill-Therapeutics-Doses-Patients-in-the-First-Cohort-of-the-Phase-12-SOLA...
Comments